ProCE Banner Activity

Phase II DREAMM-6 Arm B: Preliminary Analysis of Belantamab Mafodotin + Bortezomib/Dexamethasone in R/R MM

Slideset Download
Conference Coverage
Preliminary analysis reported manageable safety profile and clinical activity with belantamab mafodotin plus bortezomib/dexamethasone in ongoing phase II trial of pretreated patients with MM.

Released: December 11, 2020

Expiration: December 10, 2021

No longer available for credit.
Begin Activity

Share

Provided by

Provided by Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by educational grants from

Amgen, Inc.

AstraZeneca

Bristol Myers Squibb

Epizyme, Inc.

GlaxoSmithKline

Incyte Corporation

Janssen Biotech

Karyopharm Therapeutics Inc.

Novartis

PharmaEssentia Corp

Seagen

Takeda Oncology